18.1 Fatty Acid Oxidation, Ketogenesis, Cholesterol & Lipoproteins

18.1 Fatty Acid Oxidation, Ketogenesis, Cholesterol & Lipoproteins

Independent Study Guide Notice: Independent study guide by OpenExamPrep. This educational resource is developed independently by OpenExamPrep and is not sponsored, endorsed, or affiliated with the National Board of Podiatric Medical Examiners (NBPME) or Meazure Learning.

---

Introduction to Lipid Metabolism

Lipids serve three fundamental biological mandates in human physiology: dense metabolic energy storage (triacylglycerols yielding 9 kcal/g compared to 4 kcal/g for carbohydrates and proteins), structural membrane compartmentalization (phospholipids, sphingolipids, and unesterified cholesterol), and endocrine signaling (steroid hormones, eicosanoids, and secondary messengers). On the APMLE Part I examination, lipid biochemistry is tested with heavy clinical emphasis on the enzymatic checkpoints of fatty acid oxidation, inborn errors of mitochondrial transport, the metabolic partition between ketogenesis and ketolysis, cholesterol homeostasis, and the genetic dyslipidemias that precipitate premature peripheral arterial disease (PAD) and characteristic cutaneous and tendinous xanthomas in the lower extremity.

                         Global Lipid Flux in Human Metabolism

             ADIPOSE TISSUE                       LIVER (Mitochondria & Cytosol)
             ┌──────────────┐                     ┌───────────────────────────────┐
             │ Triglycerides│                     │ Fatty Acyl-CoA                │
             └──────┬───────┘                     └───┬───────────────────────┬───┘
                    │ Lipolysis (HSL)                 │ Carnitine Shuttle     │ Cytosolic HMG-CoA
                    ▼                                 ▼ (CPT-I)               ▼ Reductase
             Free Fatty Acids ──[Serum Albumin]──> Beta-Oxidation        Cholesterol Synthesis
                                                      │                       │
                                                      ▼                       ▼
                                                 Acetyl-CoA              Lipoproteins
                                                  │      │               (VLDL, LDL, HDL)
                                      Ketogenesis │      ▼ TCA Cycle
                                                  ▼      (CO2 + H2O + ATP)
                                            Ketone Bodies
                                      (Acetoacetate, B-OHB)
                                                  │
                                                  ▼
                                        EXTRAHEPATIC TISSUES
                                       (Brain, Heart, Skeletal Muscle)
                                        Thiophorase-Dependent Ketolysis

---

Fatty Acid Activation & The Carnitine Shuttle

Before long-chain fatty acids (LCFAs, typically 14 to 20 carbons, such as palmitate [16:0]) can undergo mitochondrial beta-oxidation, they must be activated in the cytoplasm and transported across the impermeable inner mitochondrial membrane (IMM).

                       The Carnitine Shuttle Machinery

       CYTOSOL                  OUTER MITOCHONDRIAL         INNER MITOCHONDRIAL     MITOCHONDRIAL
                                     MEMBRANE                    MEMBRANE               MATRIX
  Fatty Acid + CoA + 2 ATP
         │ (Acyl-CoA Synthetase)
         ▼
    Fatty Acyl-CoA ──────────────> [ CPT-I ]
                                      │ (Inhibited by Malonyl-CoA)
    Carnitine ────────────────────────┼────────┐
                                      │        ▼
                                      └──> Fatty Acylcarnitine ───┐
                                                                  │
                                      ┌───────────────────────────┘
                                      ▼
                              [ Translocase ] ───> Fatty Acylcarnitine
                               (CACT Antiporter)          │
                                      ▲                   ▼
                                      │                [ CPT-II ] ──> Fatty Acyl-CoA
                                      └────── Carnitine ◄─┘               │
                                                                          ▼
                                                                   Beta-Oxidation

1. Fatty Acid Activation (Outer Mitochondrial Membrane / ER)

• Cytoplasmic free fatty acids are converted to high-energy fatty acyl-CoA thioesters by fatty acyl-CoA synthetase (thiokinase) located on the outer mitochondrial membrane and endoplasmic reticulum: $\text{Fatty Acid} + \text{CoA-SH} + \text{ATP} \longrightarrow \text{Fatty Acyl-CoA} + \text{AMP} + \text{PP}_i$
• The inorganic pyrophosphate ($PP_i$) generated is immediately hydrolyzed to $2 P_i$ by ubiquitous pyrophosphatase, driving the reaction irreversibly forward. Thus, activating a single fatty acid molecule consumes two high-energy phosphate equivalents (the energetic equivalent of $2 \text{ ATP} \rightarrow 2 \text{ ADP}$). Short-chain (2-4 carbons) and medium-chain (6-12 carbons) fatty acids can cross the inner mitochondrial membrane by simple diffusion without activation or carrier systems.

2. The Carnitine Shuttle (Inner Mitochondrial Membrane Entry)

Long-chain fatty acyl-CoA cannot directly cross the inner mitochondrial membrane. The carnitine shuttle translocates acyl moieties into the matrix via three sequential transport steps:

1. Carnitine Palmitoyltransferase-I (CPT-I / CAT-I): Located on the outer mitochondrial membrane. Trans-esterifies the fatty acyl group from coenzyme A to the hydroxyl group of carnitine, generating fatty acylcarnitine and releasing free cytosolic CoA-SH.
   • Rate-Limiting Step: CPT-I represents the obligate, rate-limiting control point for all mitochondrial fatty acid oxidation.
   • Allosteric Regulation: Potently and allosterically inhibited by Malonyl-CoA, the first committed intermediate of de novo fatty acid synthesis produced by acetyl-CoA carboxylase (ACC). When carbohydrate energy is abundant and insulin is elevated, active fatty acid synthesis elevates cytosolic malonyl-CoA, shutting down CPT-I. This prevents a futile cycle wherein newly synthesized fatty acids would be immediately shunted into beta-oxidation.
2. Carnitine-Acylcarnitine Translocase (CACT): An inner mitochondrial membrane antiporter that shuttles fatty acylcarnitine into the matrix while simultaneously transporting free carnitine back into the intermembrane space.
3. Carnitine Palmitoyltransferase-II (CPT-II / CAT-II): Located on the matrix-facing inner mitochondrial membrane. Reverses the trans-esterification, transferring the fatty acyl group from carnitine back to a mitochondrial matrix CoA-SH, regenerating mitochondrial fatty acyl-CoA and free carnitine.

3. Inborn Errors of Carnitine Transport & Oxidation

Systemic Primary Carnitine Deficiency

• Etiology: Autosomal recessive defect in the high-affinity organic cation transporter 2 (OCTN2 / SLC22A5), preventing cellular carnitine uptake in renal tubules, skeletal muscle, and myocardium. Carnitine is lost in urine, depleting systemic stores.
• Pathophysiology: Inability to transport long-chain fatty acids into mitochondria arrests beta-oxidation. Impaired beta-oxidation starves hepatocytes of acetyl-CoA, shutting down both gluconeogenesis (pyruvate carboxylase requires acetyl-CoA) and ketogenesis.
• Clinical Manifestations: Fasting hypoketotic hypoglycemia, generalized muscle weakness, hypotonia, dilated or hypertrophic cardiomyopathy, hepatic steatosis, and lethargy. Markedly reduced plasma carnitine levels.

Medium-Chain Acyl-CoA Dehydrogenase (MCAD) Deficiency

• Etiology: Autosomal recessive deficiency in the mitochondrial enzyme medium-chain acyl-CoA dehydrogenase, which catalyzes the first step of beta-oxidation for fatty acids 6 to 12 carbons in length.
• Pathophysiology: Long-chain fatty acids enter the matrix and undergo beta-oxidation until they reach medium-chain length (C6-C12), where degradation halts. Medium-chain acyl compounds accumulate and spill into alternative microsomal omega-oxidation, producing dicarboxylic acids (e.g., adipic and suberic acids).
• Clinical Presentation: Typically manifests in infants (6 to 24 months of age) during prolonged fasting or intercurrent infections (viral gastroenteritis, URI). Presents with severe hypoketotic hypoglycemia, hyperammonemia, metabolic acidosis, vomiting, lethargy, seizures, hepatomegaly, and coma. MCAD deficiency is a major recognized cause of sudden unexpected infant death.
• Diagnostic Hallmarks: Elevated plasma octanoylcarnitine (C8-acylcarnitine) on tandem mass spectrometry newborn screening; dicarboxylic aciduria (C6 to C10 dicarboxylic acids in urine); absent or trace urine ketones despite profound hypoglycemia.
• Management: Avoid prolonged fasting (>4 hours in neonates), maintain a high-carbohydrate, low-fat diet, and administer IV dextrose emergently during acute catabolic illness.

---

Mitochondrial Beta-Oxidation & Odd-Chain Fatty Acid Degradation

Once inside the mitochondrial matrix, fatty acyl-CoA enters the repetitive four-step cyclic pathway of beta-oxidation. Each turn of the spiral shortens the acyl chain by two carbons, releasing one molecule of Acetyl-CoA, one molecule of $FADH_2$, and one molecule of $NADH$.

                  The Four Steps of the Beta-Oxidation Spiral

          Fatty Acyl-CoA (n carbons)
                     │
                     │  Step 1: Oxidation (Acyl-CoA Dehydrogenase)
                     ├──────────────────────────> FAD ──> FADH2 (ETC Complex II)
                     ▼
          trans-delta2-Enoyl-CoA
                     │
                     │  Step 2: Hydration (Enoyl-CoA Hydratase)
                     ├──────────────────────────> H2O added across double bond
                     ▼
          L-3-Hydroxyacyl-CoA
                     │
                     │  Step 3: Oxidation (3-Hydroxyacyl-CoA Dehydrogenase)
                     ├──────────────────────────> NAD+ ──> NADH + H+ (ETC Complex I)
                     ▼
          3-Ketoacyl-CoA
                     │
                     │  Step 4: Thiolysis (Beta-Ketothiolase)
                     ├──────────────────────────> CoA-SH
                     ▼
          Fatty Acyl-CoA (n-2 carbons)  +  Acetyl-CoA (enters TCA or Ketogenesis)

Energetics of Even-Chain Fatty Acid Oxidation

For a saturated 16-carbon fatty acid (Palmitate, $C_{16}H_{32}O_2$):

• Number of Cycles: $\frac{n}{2} - 1 = \frac{16}{2} - 1 = 7\text{ cycles}$.
• Products Generated: $8\text{ Acetyl-CoA} + 7\text{ }FADH_2 + 7\text{ }NADH$.
• ATP Yield Calculation:
  • $8\text{ Acetyl-CoA} \times 10\text{ ATP (TCA cycle)} = 80\text{ ATP}$
  • $7\text{ }FADH_2 \times 1.5\text{ ATP (ETC)} = 10.5\text{ ATP}$
  • $7\text{ }NADH \times 2.5\text{ ATP (ETC)} = 17.5\text{ ATP}$
  • Gross Total $= 108\text{ ATP}$
  • Net Yield $= 108 - 2\text{ (Activation)} = \mathbf{106\text{ ATP}}$.
• Palmitate provides more than three times the ATP yield of one molecule of glucose (net 30-32 ATP), illustrating why fatty acids represent the primary energetic substrate for resting skeletal muscle and the myocardium.

Odd-Chain Fatty Acid Oxidation & Glucogenic Lipids

Natural plant lipids and marine oils contain odd-numbered carbon chains (e.g., C15, C17). Odd-chain fatty acids undergo standard beta-oxidation until the final thiolytic cleavage yields one molecule of Acetyl-CoA (2C) and one molecule of Propionyl-CoA (3C).

                      Propionyl-CoA Metabolism Pathway

               Propionyl-CoA (3C)
                     │
                     │ Propionyl-CoA Carboxylase (Requires BIOTIN / B7, ATP, CO2)
                     ▼
              D-Methylmalonyl-CoA (4C)
                     │
                     │ Methylmalonyl-CoA Epimerase
                     ▼
              L-Methylmalonyl-CoA (4C)
                     │
                     │ Methylmalonyl-CoA Mutase (Requires VITAMIN B12 / Cobalamin)
                     ▼
               Succinyl-CoA (4C) ───> Enters TCA Cycle ───> Malate ───> Gluconeogenesis

1. Propionyl-CoA Carboxylase: Adds a carboxyl group to propionyl-CoA, forming D-methylmalonyl-CoA. Requires Biotin (Vitamin $B_7$), ATP, and $CO_2$. (Deficiency of this enzyme causes Propionic Acidemia).
2. Methylmalonyl-CoA Epimerase: Converts D-methylmalonyl-CoA to the L-enantiomer.
3. Methylmalonyl-CoA Mutase: Catalyzes a carbon skeleton rearrangement to produce Succinyl-CoA. Requires 5'-deoxyadenosylcobalamin (Vitamin $B_{12}$) as an obligate cofactor.
   • Clinical Correlation: In Vitamin $B_{12}$ deficiency, methylmalonyl-CoA mutase cannot function, resulting in the massive accumulation of Methylmalonic Acid (MMA) in blood and urine, accompanied by elevated homocysteine. In contrast, pure folate deficiency exhibits elevated homocysteine but normal MMA.
   • Glucogenic Status: Succinyl-CoA is a four-carbon TCA cycle intermediate that converts to malate, exits the mitochondria, and enters cytosolic gluconeogenesis. Therefore, odd-chain fatty acids are the ONLY fatty acids capable of serving as gluconeogenic precursors in humans.

---

Ketogenesis & Extrahepatic Ketolysis

When fatty acid beta-oxidation in hepatocytes exceeds the oxidative capacity of the citric acid cycle—such as during prolonged fasting, starvation, exhaustive endurance exercise, or uncontrolled diabetic ketoacidosis (DKA)—acetyl-CoA is diverted into the synthesis of water-soluble ketone bodies.

                       The Hepatic Ketogenesis Pathway

                               2 Acetyl-CoA
                                     │
                                     │ Thiolase
                                     ▼
                              Acetoacetyl-CoA
                                     │
                                     │ + Acetyl-CoA
                                     │ Mitochondrial HMG-CoA Synthase (RATE-LIMITING)
                                     ▼
                                  HMG-CoA
                                     │
                                     │ HMG-CoA Lyase
                                     ▼
                                Acetoacetate
                                ┌────┴────────────────────────┐
           Spontaneous          │                             │ Beta-Hydroxybutyrate
         Decarboxylation        │                             │ Dehydrogenase (NADH -> NAD+)
                                ▼                             ▼
                             Acetone               Beta-Hydroxybutyrate
                       (Fruity Breath, Exhaled)    (Predominant in DKA, Blood)

1. Hepatic Ketogenesis Cascade

Ketogenesis occurs exclusively within the mitochondrial matrix of hepatocytes:

1. Condensation: Two molecules of acetyl-CoA condense via mitochondrial thiolase to form acetoacetyl-CoA.
2. Rate-Limiting Step: A third acetyl-CoA is added by mitochondrial HMG-CoA synthase to form 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA). (Note: HMG-CoA synthase has two distinct isozymes: a mitochondrial isozyme dedicated to ketogenesis, and a cytosolic isozyme dedicated to cholesterol synthesis).
3. Cleavage: HMG-CoA lyase cleaves HMG-CoA into free acetoacetate and releases acetyl-CoA.
4. Conversion to Peripheral Fuel:
   • $\beta$-Hydroxybutyrate ($\beta$-OHB): Acetoacetate is reversibly reduced to $\beta$-hydroxybutyrate by $\beta$-hydroxybutyrate dehydrogenase, coupled to the oxidation of $NADH$ to $NAD^+$. In conditions with a high mitochondrial $NADH/NAD^+$ ratio (such as active DKA or ethanol intoxication), equilibrium shifts overwhelmingly toward $\beta$-hydroxybutyrate. Consequently, $\beta$-hydroxybutyrate is the predominant circulating ketone body in DKA (often exceeding acetoacetate by a 5:1 to 10:1 ratio).
   • Acetone: Acetoacetate slowly and non-enzymatically undergoes spontaneous decarboxylation to form volatile acetone, which is excreted via the pulmonary capillaries into expired air, producing the classic fruity, sweet breath odor in patients with diabetic ketoacidosis.

2. Extrahepatic Ketolysis (Peripheral Utilization)

Ketone bodies are released from hepatocytes into the systemic circulation to serve as vital water-soluble energy fuels for extrahepatic tissues (skeletal muscle, cardiac muscle, renal cortex, and during prolonged starvation, the brain, which adapts to derive up to 60-70% of its total energy from $\beta$-hydroxybutyrate):

• In target extrahepatic mitochondria, $\beta$-hydroxybutyrate is oxidized back to acetoacetate by $\beta$-hydroxybutyrate dehydrogenase ($NAD^+ \rightarrow NADH$).
• Acetoacetate is then activated to acetoacetyl-CoA by the enzyme Thiophorase (also known as Succinyl-CoA:3-ketoacid CoA transferase / SCOT), which transfers a coenzyme A moiety from succinyl-CoA (generating succinate): $\text{Acetoacetate} + \text{Succinyl-CoA} \stackrel{\text{Thiophorase}}{\longrightarrow} \text{Acetoacetyl-CoA} + \text{Succinate}$
• Acetoacetyl-CoA is subsequently cleaved by thiolase into two molecules of acetyl-CoA, which enter the citric acid cycle for ATP generation.

---

Cholesterol Biosynthesis & Statin Pharmacology

Cholesterol is an indispensable lipid component of eukaryotic cell membranes, modulating membrane fluidity, and acts as the universal biochemical precursor for bile acids, steroid hormones (cortisol, aldosterone, testosterone, estradiol), and Vitamin D.

                     Cholesterol Biosynthesis Cascade

       3 Acetyl-CoA ───> Acetoacetyl-CoA ───> Cytosolic HMG-CoA
                                                     │
                                                     │ HMG-CoA Reductase (ER Membrane)
                                                     │ - Rate-Limiting Step
                                                     │ - Consumes 2 NADPH
                                                     │ - COMPETITIVELY INHIBITED BY STATINS
                                                     ▼
                                                 Mevalonate
                                                     │
                                                     ▼ (Multiple Phosphorylations & Decarboxylation)
                                           Isopentenyl Pyrophosphate (IPP, 5C)
                                                     │
                                                     ▼
                                           Geranyl Pyrophosphate (10C)
                                                     │
                                                     ▼
                                           Farnesyl Pyrophosphate (FPP, 15C)
                                                     │
                                                     ▼ Squalene Synthase
                                              Squalene (30C)
                                                     │
                                                     ▼ Squalene Epoxidase & Cyclase
                                              Lanosterol (30C)
                                                     │
                                                     ▼ (19-Step Modification)
                                              CHOLESTEROL (27C)

1. The Rate-Limiting Step: HMG-CoA Reductase

• Biosynthesis occurs in the cytoplasm and endoplasmic reticulum (ER) of nucleated cells, predominantly in hepatocytes and enterocytes.
• Two molecules of acetyl-CoA condense to form acetoacetyl-CoA, which condenses with a third acetyl-CoA via cytosolic HMG-CoA synthase to generate cytosolic HMG-CoA.
• HMG-CoA Reductase: An integral transmembrane glycoprotein of the endoplasmic reticulum that reduces HMG-CoA to Mevalonate, consuming two molecules of NADPH.
• This is the committed, irreversible, and rate-limiting step of de novo cholesterol biosynthesis.

2. Multi-Tiered Regulation of HMG-CoA Reductase

1. Transcriptional Regulation (SREBP-2 / SCAP):
   • Sterol Regulatory Element-Binding Protein-2 (SREBP-2) is anchored to the ER membrane complexed with SCAP (SREBP Cleavage-Activating Protein).
   • When intracellular sterol concentrations fall, SCAP undergoes a conformational shift and escorts SREBP-2 in COPII vesicles to the Golgi apparatus.
   • In the Golgi, Site-1 Protease (S1P) and Site-2 Protease (S2P) cleave SREBP-2, liberating its soluble basic helix-loop-helix transcription factor domain.
   • The liberated domain migrates to the nucleus and binds Sterol Regulatory Elements (SRE) in the promoter regions of target genes, upregulating transcription of both HMG-CoA reductase and the LDL Receptor (LDLR), stimulating both de novo synthesis and clearance of circulating LDL.
2. Post-Translational Phosphorylation (AMPK):
   • Inactivation: AMP-activated protein kinase (AMPK) phosphorylates HMG-CoA reductase, rendering it catalytically inactive. High AMP (low cellular energy) and glucagon stimulate phosphorylation, shutting down cholesterol synthesis to conserve energy.
   • Activation: Insulin activates protein phosphatase 2A, which dephosphorylates and activates HMG-CoA reductase, stimulating cholesterol synthesis in the well-fed state.
3. Proteasomal Degradation: Rising intracellular concentrations of cholesterol and oxysterols trigger ubiquitination of HMG-CoA reductase, directing it to the 26S proteasome for degradation.

3. Statin Therapeutics (HMG-CoA Reductase Inhibitors)

• Mechanism: Statins (Atorvastatin, Rosuvastatin, Simvastatin, Pravastatin) possess a structural component that closely mimics the 3-hydroxyglutaryl moiety of HMG-CoA. They act as reversible competitive inhibitors of HMG-CoA reductase, binding to its active catalytic site and blocking mevalonate synthesis.
• Downstream Cellular Consequence: Decreased intracellular hepatic cholesterol levels relieve SCAP inhibition, triggering SREBP-2 cleavage and nuclear translocation. SREBP-2 dramatically upregulates LDL receptor transcription on the hepatocyte surface. The expanded pool of cell-surface LDL receptors clears circulating atherogenic LDL particles from the bloodstream via receptor-mediated endocytosis, lowering serum LDL-C by 30% to 60%.
• Adverse Effects: Statin-associated myopathy/myositis (elevated serum creatine kinase [CK]), myalgias in large muscle groups of the lower extremity (calves, thighs), asymptomatic elevations in hepatic transaminases, and rare rhabdomyolysis (potentiated by concurrent fibrate therapy, particularly gemfibrozil, which inhibits statin glucuronidation).

---

Lipoprotein Structure, Apolipoproteins & Dynamics

Lipids are completely insoluble in aqueous plasma and must be packaged into spherical, micelle-like macromolecular complexes termed lipoproteins for vascular transport. Each particle possesses a nonpolar hydrophobic lipid core surrounded by an amphipathic monolayer of phospholipids, unesterified cholesterol, and apolipoproteins.

                             Spherical Lipoprotein Architecture

                                  Phospholipid Monolayer
                                 (Hydrophilic Choline Heads Outward)
                                        │
                                   ○ ○ ○ ○ ○ ○ ○
                                ○                 ○ ── Apolipoprotein (e.g., ApoB-100)
                              ○   HYDROPHOBIC CORE  ○
                             ○   - Triglycerides     ○ ── Unesterified Cholesterol
                             ○   - Cholesterol Esters○
                              ○                     ○
                                ○                 ○ ── Apolipoprotein (e.g., ApoE)
                                   ○ ○ ○ ○ ○ ○ ○

Apolipoprotein Classification & Specific Roles

                           The Lipoprotein Transport Cascade

    EXOGENOUS PATHWAY (Dietary Lipids)              ENDOGENOUS PATHWAY (Hepatic Lipids)
    ┌─────────────────────────────┐                 ┌─────────────────────────────┐
    │ Intestinal Enterocytes      │                 │ Hepatocytes                 │
    │ Secretes: CHYLOMICRONS      │                 │ Secretes: VLDL              │
    │ (ApoB-48, ApoC-II, ApoE)    │                 │ (ApoB-100, ApoC-II, ApoE)   │
    └──────────────┬──────────────┘                 └──────────────┬──────────────┘
                   │                                               │
                   ▼                                               ▼
            Capillary Bed                                   Capillary Bed
        [ LPL Activated by ApoC-II ]                    [ LPL Activated by ApoC-II ]
                   │                                               │
         FFA to Muscle & Adipose                         FFA to Muscle & Adipose
                   │                                               │
                   ▼                                               ▼
          Chylomicron Remnant                                     IDL
          (ApoB-48, ApoE)                                 (ApoB-100, ApoE)
                   │                                        ┌──────┴──────┐
                   ▼ Hepatic LDLR / LRP                     ▼             ▼
          Cleared by Liver (ApoE)                   Liver Uptake   Hepatic Lipase (HL)
                                                                          ▼
                                                                         LDL
                                                                     (ApoB-100)
                                                                          │
                                                       Peripheral LDLR ◄──┴──► Hepatic LDLR

1. Chylomicrons (Exogenous Dietary Pathway)

• Synthesized in intestinal enterocytes from dietary triglycerides, cholesterol, and fat-soluble vitamins.
• Packaged with ApoB-48 and secreted into mesenteric lacteals, entering the systemic venous circulation via the thoracic duct (bypassing the hepatic portal system).
• In plasma, nascent chylomicrons acquire ApoC-II and ApoE from circulating mature HDL.
• In capillary beds of adipose tissue and skeletal muscle, endothelial Lipoprotein Lipase (LPL) (activated by ApoC-II) hydrolyzes core triglycerides into free fatty acids (used for energy or re-esterified for storage) and glycerol.
• As triglycerides are depleted, ApoC-II is transferred back to HDL. The resulting chylomicron remnant (rich in cholesterol esters, retaining ApoB-48 and ApoE) binds hepatic LDL receptors and LRP via ApoE, undergoing endocytic clearance by hepatocytes.

2. VLDL & IDL (Endogenous Hepatic Pathway)

• Synthesized in hepatocytes to export endogenous triglycerides to peripheral tissues.
• Packaged with full-length ApoB-100; acquires ApoC-II and ApoE from HDL.
• Endothelial LPL hydrolyzes triglycerides in adipose and muscle, reducing particle volume to form Intermediate-Density Lipoprotein (IDL).
• IDL retains ApoB-100 and ApoE. Approximately 50% of IDL is cleared directly by the liver via ApoE binding to LDLR. The remaining IDL undergoes further triglyceride hydrolysis by hepatic lipase (HL) in hepatic sinusoids, losing ApoE to become Low-Density Lipoprotein (LDL).

3. LDL & Atherogenesis

• LDL carries approximately 70% of total circulating plasma cholesterol. Its sole apolipoprotein is ApoB-100.
• Primary role is delivering cholesterol to peripheral tissues (and back to liver) via LDL Receptor-Mediated Endocytosis:
  • ApoB-100 binds the extracellular domain of the LDLR on clathrin-coated pits.
  • The complex is internalized via clathrin-coated endosomes; endosomal acidification dissociates LDL from the receptor; the receptor recycles back to the plasma membrane.
  • The endosome fuses with a lysosome, where acid lipases degrade ApoB-100 to amino acids and hydrolyze cholesterol esters into free unesterified cholesterol.
  • Free intracellular cholesterol suppresses HMG-CoA reductase, suppresses LDLR transcription (via SREBP-2), and activates ACAT (Acyl-CoA:Cholesterol Acyltransferase) to store excess cholesterol as intracellular droplet esters.
• Atherogenesis in Lower Extremity PAD: When plasma LDL is elevated, excess particles penetrate the permeable endothelial barrier of arteries (e.g., femoral, popliteal, tibial arteries). Within the subendothelial intima, trapped LDL undergoes chemical oxidation (oxLDL). oxLDL stimulates endothelial cells to express adhesion molecules (VCAM-1, ICAM-1) and monocyte chemoattractants. Recruited monocytes differentiate into macrophages, which engulf oxLDL via unregulated Scavenger Receptors (SR-A / CD36). Unrestrained lipid ingestion transforms macrophages into lipid-laden foam cells, forming the pathognomonic fatty streak, followed by smooth muscle migration, collagen deposition, fibrous cap formation, and atherosclerotic plaque progression.

4. HDL & Reverse Cholesterol Transport

• HDL is synthesized and secreted as an empty, disk-shaped (nascent) particle by the liver and small intestine, composed primarily of ApoA-I and phospholipids.
• Reverse Cholesterol Transport:
  • Nascent HDL extracts excess unesterified free cholesterol from peripheral cells and arterial macrophages via ABCA1 and ABCG1 lipid transporters.
  • LCAT (Lecithin-Cholesterol Acyltransferase / PCAT): Activated by ApoA-I on the HDL surface. LCAT transfers a fatty acid from phosphatidylcholine (lecithin) to free cholesterol, generating cholesterol esters and lysolecithin. Hydrophobic cholesterol esters migrate into the particle core, converting flat nascent HDL into mature, spherical $HDL_3$ and $HDL_2$.
  • CETP (Cholesteryl Ester Transfer Protein): Mediates the reciprocal exchange of cholesterol esters from mature HDL to triglyceride-rich particles (VLDL, IDL, LDL) in exchange for triglycerides. This allows peripheral cholesterol to return to the liver indirectly via LDL-LDLR clearance.
  • Direct Hepatic Uptake: HDL delivers cholesterol esters directly to hepatocytes via the Scavenger Receptor Class B Type 1 (SR-B1) without particle degradation, allowing HDL to re-enter circulation.
  • Circulating Reservoir: HDL serves as a circulating storage depot for ApoC-II and ApoE, donating them to nascent chylomicrons and VLDL and retrieving them upon triglyceride depletion.

---

Familial Dyslipidemias & Lower Extremity Phenotypes

Inherited genetic defects in apolipoproteins, cell-surface receptors, or lipid-processing enzymes produce characteristic patterns of plasma lipid elevation and pathognomonic clinical findings.

                    Classification of Familial Dyslipidemias

   TYPE I: Hyperchylomicronemia        TYPE IIa: Hypercholesterolemia      TYPE III: Dysbetalipoproteinemia
   - Defect: LPL or ApoC-II            - Defect: LDLR or ApoB-100          - Defect: ApoE2/E2 homozygous
   - Elevated: Chylomicrons (TG >1000) - Elevated: LDL (Cholesterol >300)  - Elevated: Chylomicron Remnants & IDL
   - Eruptive Xanthomas                - ACHILLES TENDON XANTHOMAS         - PALMAR CREASE XANTHOMAS
   - Pancreatitis                      - Severe Accelerated Atherosclerosis- Premature CAD & PAD
   - NO Premature CAD                  - Xanthelasma, Arcus Senilis